Free Trial
NASDAQ:CTSO

Cytosorbents Q1 2025 Earnings Report

Cytosorbents logo
$0.94 -0.07 (-6.93%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$0.96 +0.02 (+1.60%)
As of 05/2/2025 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytosorbents EPS Results

Actual EPS
N/A
Consensus EPS
-$0.08
Beat/Miss
N/A
One Year Ago EPS
N/A

Cytosorbents Revenue Results

Actual Revenue
N/A
Expected Revenue
$9.01 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cytosorbents Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Cytosorbents Earnings Headlines

The Man I Turn to In Times Like This
A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
See More Cytosorbents Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cytosorbents? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cytosorbents and other key companies, straight to your email.

About Cytosorbents

Cytosorbents (NASDAQ:CTSO) engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

View Cytosorbents Profile

More Earnings Resources from MarketBeat